Onlookers ponder Biocryst's likely place in HAE as kallikrein inhibitor advances
As Biocryst Pharmaceuticals Inc. prepared to close its $45 million financing round last week, work continued with BCX7353 and second-generation compounds for hereditary angioedema (HAE). So did speculation about the oral, second-generation kallikrein inhibitor's chances in the crowded HAE space, as company watchers mulled interim outcomes unveiled in late February from APeX-1, a phase II dose ranging trial.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST